Skip to main content
eScholarship
Open Access Publications from the University of California

Open Access Policy Deposits

This series is automatically populated with publications deposited by UCLA David Geffen School of Medicine Department of Molecular & Medical Pharmacology researchers in accordance with the University of California’s open access policies. For more information see Open Access Policy Deposits and the UC Publication Management System.


Cover page of Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer

Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer

(2025)

Apolipoproteins are the defining functional component of lipoproteins and play critical roles in lipid transport and metabolism. High-density lipoprotein (HDL) and its primary functional constituent, apolipoprotein A-I, are of particular importance because of anti-inflammatory and antioxidant properties. Apolipoprotein mimetic peptides are short-chain amino acids designed to mimic the functions and alpha-helical structure of endogenous apolipoproteins and have demonstrated efficacy in ameliorating animal models of cardiovascular disease (CVD) and cancer. The mechanisms underlying the mimetics are yet to be fully elucidated, but a comprehensive review of the literature suggests that the peptides attack pathways shared in the pathophysiology of both diseases. This review also discusses the many pre-clinical studies on the mimetic peptides, highlighting possible mechanisms at work in each. Proposed mechanisms of protection against CVD and cancer include binding and removal of pro-inflammatory oxidized lipids, reduction in reactive oxygen species, and modulation of immune cell populations. Additionally, nanoparticles (NP) formulations incorporating apolipoprotein mimetic peptides or recombinant apolipoproteins have exhibited anti-atherogenic and anti-cancer activity. To date, clinical trials to assess the effect of reconstituted HDL NPs on CVD outcomes have not shown significant improvement. The large body of successful animal studies on apolipoproteins and apolipoprotein mimetic peptides presents a disconnect between pre-clinical and clinical efficacy, highlighting the need for a more complete understanding of the underlying pathways and mechanisms.

Cover page of Assessment of PSMA PET/CT derived predictive markers for 177 Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.

Assessment of PSMA PET/CT derived predictive markers for 177 Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.

(2025)

5079 Background: 177 Lu-PSMA-617 (Lu-PSMA) contributes to prolong progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed after chemotherapy. Pretherapeutic prostate-specific membrane antigen (PSMA) PET/CT information can be used to predict Lu-PSMA therapy response patterns and outcomes, with various quantitative and visual methods proposed. We aimed to test various proposed PSMA PET/CT-derived outcome predictors in the U.S. expanded-access program (EAP) cohort. Methods: Patients enrolled in the EAP (NCT04825652) for Lu-PSMA at 3 institutions with available pretherapeutic PSMA PET/CT and outcomes were included in this analysis. Quantitative analysis was performed for all tumor lesions on PSMA PET/CT with semi-automatically contouring. Total tumor volume (TV), total tumor SUVmean, total tumor SUVmax, total lesion uptake (TLU = TV * SUVmean), total lesion quotient (TLQ = TV / SUVmean), and quantitative PSMA PET tumor–to–salivary gland ratio (qPSG: high, ≥ 1.5; intermediate, 0.5–1.5; low, ≤ 0.5) were calculated for each patient. For visual analysis, visual PSG (vPSG: high, most of the lesions showed higher uptake than the parotid glands; intermediate, neither low nor high; low, most of the lesions showed lower uptake than the parotid glands) and heterogeneity and intensity of tumors (HIT: 1, SUVmax < 15; 2, 15–79 with heterogeneous intensity; 3, 15–79 with homogeneous intensity; 4, ≥ 80) scores were used for assessment. Outcomes included a prostate-specific antigen (PSA) PFS, and OS. We evaluated the predictive performance of each model using Cox proportional hazards regression analysis and assessed their performance with the concordance index (c-index). Results: In total, 88 patients who received Lu-PSMA within the EAP between May 2021 and March 2022 were eligible and included in this analysis. For the PSA PFS, the total tumor SUVmean achieved the highest c-index of 0.678 (HR 0.91 [95% CI, 0.85–0.97], p = 0.004), followed by the total tumor SUVmax with a c-index of 0.640 (HR 0.99 [95% CI, 0.99–1.00], p = 0.034). For OS, the TLQ achieved the highest c-index of 0.658 (HR 1.01 [95% CI, 1.00–1.01], p < 0.001), followed by the total tumor SUVmean with a c-index of 0.634 (HR 0.89 [95% CI, 0.83–0.96], p = 0.004). The HIT score showed the third highest c-index of 0.632; however, when using score 1 as the reference, the HR did not exhibit a sequential trend across ordinal categories as anticipated. Conclusions: Quantitative analysis outperformed visual analysis in predicting the outcome of mCRPC with Lu-PSMA therapy in the EAP cohort. Total tumor SUVmean was identified as the most robust predictor for PSA PFS, while TLQ showed promise as a predictor for OS. Incorporating these predictors into clinical decision-making for pre-Lu-PSMA therapy could aid in patient selection and treatment planning. Clinical trial information: NCT04825652 .

Cover page of [99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer

[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer

(2025)

Purpose

Radioligand therapy (RLT) targeting PSMA (prostate-specific membrane antigen) has transformed the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, bone marrow depletion remains a common side effect, particularly in patients with extensive bone metastases or prior myelotoxic therapies. This study evaluated [99mTc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve to guide myelotoxic treatment decisions.

Methods

Ten mCRPC patients with extensive osseous tumor load on [18F]F-PSMA PET/CT underwent [99mTc]Tc-antigranulocyte scintigraphy to assess bone marrow reserve and RLT eligibility (interval: 26.6 ± 18.5 days). Visual comparison of both modalities evaluated tumor-bone marrow overlap. Patients without significant co-localization received RLT ([177Lu]Lu-PSMA or [225Ac]Ac-PSMA) with laboratory monitoring before and between the cycles.

Results

No significant co-localization between viable bone marrow and PSMA-positive metastases was observed in 9/10 (90.0%) patients. Two other patients were excluded from RLT due to contraindications. Of the remaining seven patients, 2/7 (28.6%) underwent subsequent [177Lu]Lu-PSMA therapy, 2/7 (28.6%) [225Ac]Ac-PSMA therapy and 2/7 (28.6%) [225Ac]Ac-[177Lu]Lu-PSMA therapy. 1/7 (14.3%) received a single cycle of [177Lu]Lu-PSMA, which was then followed by [225Ac]Ac-PSMA therapy. Follow-up laboratory results showed no significant changes from baseline (p > 0.05).

Conclusion

[99mTc]Tc-antigranulocyte scintigraphy may support the assessment of bone marrow reserve in patients with extensive bone metastases. Spatial mismatch was associated with no significant myelotoxicity, whereas high congruence may increase the risk. No fixed thresholds currently exist; thus, this method should be regarded as a supplementary tool in complex cases and future studies are needed to define the critical bone marrow volume.

Cover page of Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

(2025)

Background and objective

We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study.

Methods

We included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 and 2022. Investigator sites were split 2:1 into the development (4044 patients) and validation (2084 patients) cohorts. We created nomograms of version 2 (PPP2) based on Cox regression models with the least absolute shrinkage and selection operator penalty for overall survival (development cohort). Performance of both nomograms was measured using Harrell's C-index and calibration plots and a head-to-head comparison with the National Comprehensive Cancer Network (NCCN) risk score by receiver operating characteristic curves (validation cohort).

Key findings and limitations

Predictors were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b], and visceral metastases [M1c]), PSMA expression score, and total lesion count (visual PPP2) or total tumour volume (quantitative PPP2). C-indices (95% confidence interval) in the validation cohort were 0.80 (0.78-0.82; visual) and 0.80 (0.79-0.82; quantitative), respectively. Accuracy of both the PPP2 nomograms was superior to the NCCN risk score (n = 1034, area under the curve 0.84 vs 0.76; p < 0.001). The retrospective design represents a limitation of the study.

Conclusions and clinical implications

PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org).

Cover page of 68Ga-FAPI and 18F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients

68Ga-FAPI and 18F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients

(2025)

Introduction

To determine the best therapeutic strategy for muscle-invasive bladder cancer (BC), the accuracy of lymph node staging is of paramount importance. However, diagnostic performance of conventional computed tomography in BC prior to radical cystectomy (RC) remains unsatisfactory. There is an increased interest in evaluating 18F-FAPI PET/CT for hybrid imaging due to their logistical advantages compared to [68Ga]Ga-based FAPI tracers in clinical routine. Recently, the potential diagnostic value of [68Ga]Ga-FAPI- 46 PET/CT was demonstrated in BC. Thus, we aimed to examine the diagnostic performance of [18F]F-FAPI- 74 and [68Ga]Ga-FAPI- 46 PET/CT for preoperative evaluation of locoregional lymph node metastases.

Methods

Fifty-one patients underwent FAPI PET/CT with either [68Ga]Ga-FAPI- 46 (n = 23) or [18F]F-FAPI- 74 (n = 28) prior to RC and PLND. SUVmax, SUVmean and the ratio between the SUVmax of lymph nodes and the SUVmean of the background (SUVmax_lymph node/SUVmean_background) were assessed. Additionally, short axis diameter (SAD) for a representative lymph node were documented in each lymph node region (n = 123) and compared to histopathological findings. Each scan was interpreted visually and quantitatively. ROC-analyses were performed to determine cut-off values with highest diagnostic accuracy.

Results

20/123 (16.3%) lymph node regions showed UC lymph node metastases. Histopathologically positive lymph nodes were associated with a significantly higher FAPI uptake compared to negative lymph nodes regarding SUVmax, SUVmean values and SUVmax_lymph node/SUVmean_background ratios. Visual analysis based on FAPI uptake showed a sensitivity and specificity, PPV and NPV of 63.6%, 95.8%, 77.7%, and 92.0% for [68Ga]Ga-FAPI- 46 and 55.5%, 98.1%, 83.3%, and 93.1% for [18F]F-FAPI- 74, respectively. ROC analysis revealed an optimal cut-off for SUVmax, SUVmean and SUVmax_lymph node/SUVmean_background of 1.35, 1.20 and 5.95 for [68Ga]Ga-FAPI- 46 and 1.55, 1.25 and 4.15 for [18F]F-FAPI- 74 to discriminate between histopathologically proven lymph node metastases and non-malignant lymph nodes resulting for example using SUVmax in a sensitivity and specificity, PPV and NPV of 81.8%, 89.5%, 64.2%, 95.5% for [68Ga]Ga-FAPI- 46 and 100%, 81.8%, 47.3%, 100% for [18F]F-FAPI- 74, respectively. CT visual analysis of locoregional lymph nodes showed a sensitivity, specificity, PPV and NPV of 30.0%, 97.0%, 66.6% and 87.7%, respectively. ROC analysis regarding SAD revealed a cutoff at 0.8 cm with a sensitivity, specificity, PPV and NPV of 75.0%, 84.4%, 48.3%, 94.5%, respectively.

Conclusion

Overall, FAPI PET imaging shows a significantly higher sensitivity than CT analysis for detection of locoregional lymph node metastases in UC. [18F]F-FAPI- 74 demonstrates a comparable diagnostic performance compared to [68Ga]Ga-FAPI- 46. Of note, the quantitative analysis with a pre-defined SUVmax as well as SUVmean values, and SUVmax_lymph node/SUVmean_background ratio-based cut-offs provided a higher sensitivity compared to visual assessment.

Cover page of An activation-based high throughput screen identifies caspase-10 inhibitors

An activation-based high throughput screen identifies caspase-10 inhibitors

(2025)

Caspases are a family of highly homologous cysteine proteases that play critical roles in inflammation and apoptosis. Small molecule inhibitors are useful tools for studying caspase biology, complementary to genetic approaches. However, achieving inhibitor selectivity for individual members of this highly homologous enzyme family remains a major challenge in developing such tool compounds. Prior studies have revealed that one strategy to tackle this selectivity gap is to target the precursor or zymogen forms of individual caspases, which share reduced structural homology when compared to active proteases. To establish a screening assay that favors the discovery of zymogen-directed caspase-10 selective inhibitors, we engineered a low-background and high-activity tobacco etch virus (TEV)-activated caspase-10 protein. We then subjected this turn-on protease to a high-throughput screen of approximately 100 000 compounds, with an average Z' value of 0.58 across all plates analyzed. Counter screening, including against TEV protease, delineated bona fide procaspase-10 inhibitors. Confirmatory studies identified a class of thiadiazine-containing compounds that undergo isomerization and oxidation to generate cysteine-reactive compounds with caspase-10 inhibitory activity. In parallel, mode-of-action studies revealed that pifithrin-μ (PFTμ), a reported TP53 inhibitor, also functions as a promiscuous caspase inhibitor. Both inhibitor classes showed preferential zymogen inhibition. Given the generalized utility of activation assays, we expect our screening platform to have widespread applications in identifying state-specific protease inhibitors.

Cover page of Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.

Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.

(2025)

SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100-150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.

Cover page of Differing genetics of saline and cocaine self-administration in the hybrid mouse diversity panel

Differing genetics of saline and cocaine self-administration in the hybrid mouse diversity panel

(2025)

To identify genes that regulate the response to the potentially addictive drug cocaine, we performed a control experiment using genome-wide association studies (GWASs) and RNA-Seq of a panel of inbred and recombinant inbred mice undergoing intravenous self-administration of saline. A linear mixed model increased statistical power for analysis of the longitudinal behavioral data, which was acquired over 10 days. A total of 145 loci were identified for saline compared to 17 for the corresponding cocaine GWAS. Only one locus overlapped. Transcriptome-wide association studies (TWASs) using RNA-Seq data from the nucleus accumbens and medial frontal cortex identified 5031434O11Rik and Zfp60 as significant for saline self-administration. Two other genes, Myh4 and Npc1, were nominated based on proximity to loci for multiple endpoints or a cis locus regulating expression. All four genes have previously been implicated in locomotor activity, despite the absence of a strong relationship between saline taking and distance traveled in the open field. Our results indicate a distinct genetic basis for saline and cocaine self-administration, and suggest some common genes for saline self-administration and locomotor activity.

Cover page of Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

(2025)

BACKGROUND: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. MAIN BODY: This selection of highlights provides commentary on 24 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. CONCLUSION: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Cover page of Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma

Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma

(2025)

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality, largely due to late-stage diagnosis. Reliable early detection methods are critically needed. PDAC-derived extracellular vesicles (EVs) carry molecules that reflect their parental tumor cells and are detectable in early disease stages, offering a promising noninvasive diagnostic approach. Here, a streamlined PDAC EV Surface Protein Assay for quantifying PDAC EV subpopulations in 300-µL plasma through a two-step workflow is presented: i) click chemistry-mediated EV enrichment using EV Click Beads and trans-cyclooctene-grafted antibodies targeting three PDAC EV-specific surface proteins (MUC1, EGFR, and TROP2), and ii) quantification of enriched PDAC EVs through reverse transcription-quantitative polymerase chain reaction. The three PDAC EV-specific surface proteins are identified using a bioinformatics framework and validated on PDAC cell lines and tissue microarrays. The resultant PDAC EV Score, derived from signals of the three PDAC EV subpopulations, demonstrates robust differentiation of PDAC patients from noncancer controls, with area under the receiver operating characteristic curves of 0.94 in the training (n = 124) and 0.93 in the validation (n = 136) cohorts. This EV-based diagnostic approach successfully exploits PDAC EV subpopulations as novel biomarkers for PDAC early detection, translating PDAC surface proteins into an EV-based liquid biopsy platform.